Companies › BeBetter Med
5 active drug programs in 7 registered trials: 3 Phase 2, 2 Phase 3, 2 Phase 1; Oncology, Cardiovascular; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Ifupinostat Hydrochloride for Injection (BEBT-908) Histone deacetylase (HDAC) inhibitor | HDAC | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Dec 2028 |
| BEBT-209 | – | Phase 3 | HR+/HER2- Locally Advanced, Metastatic Breast Cancer; Locally Advanced Triple-negative Breast Cancer | Jun 2030 |
| BEBT-109 EGFR exon 20 insertion inhibitor | EGFR | Phase 2 | Non-Small Cell Lung Cancer; Non Small Cell Lung Cancer | Jun 2027 |
| BEBT-507 Injection | – | Phase 1 | Polycythemia Vera | Jan 2028 |
| BEBT-701 Injection | – | Phase 1 | Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol | Nov 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06706713 | BEBT-109 | Phase 2 | Non-Small Cell Lung Cancer | Oncology | Dec 2025 |
| NCT06998108 | BEBT-209 | Phase 3 | HR+/HER2- Locally Advanced, Metastatic Breast Cancer | Oncology | Dec 2025 |
| NCT06514027 | BEBT-109 | Phase 2 | Non Small Cell Lung Cancer | Oncology | Jun 2027 |
| NCT07012109 | BEBT-507 Injection | Phase 1 | Polycythemia Vera | Oncology | Jan 2028 |
| NCT07368608 | BEBT-701 Injection | Phase 1 | Mild to Moderate Hypertension and Elevated Low-Density Lipoprotein Cholesterol | Cardiovascular | Nov 2028 |
| NCT06792253 | Ifupinostat Hydrochloride for Injection (BEBT-908) | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Oncology | Dec 2028 |
| NCT07544056 | BEBT-209 | Phase 2 | Locally Advanced Triple-negative Breast Cancer | Oncology | Jun 2030 |
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Jiangsu Alphamab Biopharmaceuticals Nanjing Sanhome Pharmaceutical Jiangsu Aosaikang Pharmaceutical ArriVent BioPharma Wayshine Biopharm
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.